This Center Tests Drug Combinations Guided by Tumor Biology
This institute has launched an initiative to test new drug combinations, which could be effective in treating both adults and children. The drug combinations would reportedly target specific tumor alterations.
The National Cancer Institute (NCI) is known for its clinical trials and researching new kinds of therapies useful in cancer treatment. NCI’s new initiative Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice, or ComboMATCH, boasts about it being the largest of its kind that is involved in testing combination drugs, which could prove useful in treating patients with specific tumor alterations. The research on combination drugs is guided by tumor biology.
ComboMATCH trials will evaluate the effectiveness of two targeted drugs or a chemotherapy drug plus a targeted drug. An article published by the National Cancer Institute mentions the following:
“ComboMATCH comprises numerous phase 2 treatment trials that will each evaluate a drug combination—usually either two targeted drugs or a targeted drug plus a chemotherapy drug. Some trials will include patients with specific changes in their cancer cells, no matter where the cancer arose in the body, whereas others will enroll patients with specific cancer types.’
‘The majority of treatments that patients get nowadays are not genomically determined,’ said James H. Doroshow, M.D., director of NCI’s Division of Cancer Treatment and Diagnosis. ‘With ComboMATCH, we’re trying to show that genomic abnormalities can be used to determine the most effective treatment combinations for patients,’” the article further states
Patients will be selected for trials in the ComboMATCH initiative after they “provide a pretreatment tumor biopsy specimen for genomic profiling.” This will enable the researchers to probe various other questions about the combination drugs, such as why specific combinations are effective or not effective.
The National Cancer Institute article reads:
“There are several ways in which patients with locally advanced or metastatic solid tumors will be identified for possible participation in ComboMATCH. In recent years, genomic testing of tumors has become a standard part of care for people with many cancer types. A doctor at any of the community hospitals and cancer centers participating in ComboMATCH can refer their patient for additional eligibility screening if the patient’s test results show that they have a particular alteration being investigated in one of the treatment trials…”
In the next episode, we will explore other interesting treatments that are creating waves in the field of cancer research.
How did you find this information? Please mention this in the comments section. We would also like to know the kind of content you want to watch, and we will try to create it for you. For more news and updates, follow Airr News.
#CancerResearch #ClinicalTrials #ComboMatch #DrugCombinations #TargetedDrugs #Immunitherapy #chemotherapy #ChemoDrugs #NationalCancerInstitute #NCI #Tumor #TumorAlterations #FightingCancer #CancerSurvivors #AirrNews #NewsInEnglish
